Genetic Heterogeneity of the NS5A Gene of Hepatitis C Virus and Early Response to Interferon-α

Journal of Infectious Diseases

Volumn 188, Issue 9, 2003, Pages 1367-1370

  Boulestin, Anne ^a,b   Sandres Saune, Karine ^a   Payen, Jean Louis ^b   Rostaing, Lionel ^c   Pasquier, Christophe ^a   Izopet, Jacques ^a  

^a Laboratoire de Virologie   (France)

^b CHU PURPAN   (France)

^c CHU RANGUEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BINDING PROTEIN; DOUBLE STRANDED RNA;

ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME BINDING; GENETIC HETEROGENEITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MOLECULAR CLONING; NS5A GENE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; SEQUENCE ANALYSIS; UNINDEXED SEQUENCE; VIRUS GENE; VIRUS LOAD; VIRUS STRAIN;

ANTIVIRAL AGENTS; AREA UNDER CURVE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; RNA, VIRAL; STATISTICS, NONPARAMETRIC; VARIATION (GENETICS); VIRAL LOAD; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 0242721028     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/379037     Document Type: Article

References (15)

1. Enomoto N, Sakuma I, Asahina Y, et al. Comparison of full-length sequences of interferon-sensitive and -resistant hepatitis C virus 1b: sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 1995; 96:224-30.
2. Gale M Jr, Blakely CM, Kwieciszewski B, et al. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol 1998; 18:5208-18.
3. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282:103-7.
4. Jessner W, Gschwantler M, Steindl-Munda P, et al. Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study. Lancet 2001; 358:1241-2.
5. Chatelut E, Rostaing L, Gregoire N, et al. A pharmacokinetic model for alpha interferon administered subcutaneously. Br J Clin Pharmacol 1999; 47:365-71.
6. Berg T, Mas Marques A, Hohne M, Wiedenmann B, Hopf U, Schreier E. Mutations in the E2-PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment. Hepatology 2000; 32:1386-95.
7. Boulestin A, Sandres-Saune K, Payen JL, et al. Genetic heterogeneity of the envelope 2 gene and eradication of hepatitis C virus after a second course of interferon-alpha. J Med Virol 2002; 68:221-8.
8. Gerotto M, Dal Pero F, Sullivan DG, et al. Evidence for sequence selection within the non-structural 5A gene of hepatitis C virus type 1b during unsuccessful treatment with interferon-alpha. J Viral Hepat 1999; 6:367-72.
9. Zeuzem S, Schmidt JM, Lee JH, von Wagner M, Teuber G, Roth WK. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover. Hepatology 1998; 28:245-52.
10. Zeuzem S, Herrmann E, Lee JH, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001; 120:1438-47.
11. Pawlotsky JM, Germanidis G, Neumann AU, Pellerin M, Frainais PO, Dhumeaux D. Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations. J Virol 1998; 72:2795-805.
12. Nousbaum J, Polyak SJ, Ray SC, et al. Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy. J Virol 2000; 74:9028-38.
13. Schiappa DA, Mittal C, Brown JA, Mika BP. Relationship of hepatitis C genotype 1 NS5A sequence mutations to early phase viral kinetics and interferon effectiveness. J Infect Dis 2002; 185:868-77.
14. Polyak SJ, Khabar KS, Paschal DM, et al. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J Virol 2001; 75:6095-106.
15. Gutterman JU, Fine S, Quesada J, et al. Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Intern Med 1982; 96:549-56.